MedTrace Logo

Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy

NCT07471282 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2026-03-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI \< 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Conditions

Interventions

DRUG

Tenecteplase (0.0938mg/kg)

Post-mechanical thrombectomy bridging therapy with intra-arterial tenecteplase (0.0938 mg/kg) for incomplete recanalization (2b ≤ eTICI \< 3).

DRUG

Placebo

Post-mechanical thrombectomy bridging "therapy" with intra-arterial placebo (0.0938 mg/kg) for incomplete recanalization (2b ≤ eTICI \< 3).

Sponsors & Collaborators

  • Chuansheng Zhao

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2028-12-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07471282 on ClinicalTrials.gov